{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T04:41:55Z","timestamp":1777956115006,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"U.S. Department of Veterans Affairs,United States","award":["HX0003533-01A1"],"award-info":[{"award-number":["HX0003533-01A1"]}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["1IK2BX006525-01A1"],"award-info":[{"award-number":["1IK2BX006525-01A1"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers (ACEI\/ARBs) is a common component of many nephrotoxin-associated acute kidney injury (NA-AKI) prevention strategies, though their intrinsic nephrotoxic potential has been increasingly challenged. We hypothesized that ACEI\/ARBs would associate with increased overall AKI and stage 2\/3 AKI in hospitalized adults receiving multiple nephrotoxins.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included adult patients admitted to the University of Iowa Hospital for \u2265\u20093 days from 2014 to 2022. We compared patients receiving 2 nephrotoxins to patients receiving 3, with one being an ACEI\/ARB. This allowed us to compare patients not counted as having a high nephrotoxin exposure to a group that would due to an additional ACEI\/ARB. The primary outcome was AKI within 7 days of initial exposure. Secondary outcomes included stage 2\/3 AKI and AKI occurring within 3 and 14 days of initial exposure. Generalized estimating equations with robust standard errors were used to estimate associations and incorporated inverse probability of treatment weighting (IPTW) based on 30 clinical covariates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The primary analysis included 15,438 patients exposed to two non-ACEI\/ARB nephrotoxins, of which 1,106 (7.2%) also received an ACEI\/ARB. Groups were well-matched after IPTW. Adjusted risk of AKI was 25% (95% CI 22\u201329%) in the ACEI\/ARB group, and 20% (19\u201321%) in the comparator group (adjusted odds ratio 1.35, 95% CI 1.07\u20131.71). In contrast, ACEI\/ARB exposure was not associated with increased risk of stage 2\/3 AKI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a cohort of hospitalized patients receiving multiple nephrotoxic agents, ACEI\/ARBs were associated with higher risks of AKI, but not higher rates of stage 2\/3 AKI.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-026-04884-3","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T08:30:10Z","timestamp":1774513810000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impacts of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on rates of acute kidney injury in hospitalized adults receiving multiple nephrotoxins"],"prefix":"10.1186","volume":"27","author":[{"given":"Michael","family":"Tabet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Vaughan-Sarrazin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian C.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spyridon","family":"Fortis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Jalal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Misurac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin R.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"issue":"4","key":"4884_CR1","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.kint.2018.11.030","volume":"95","author":"HG Sparrow","year":"2019","unstructured":"Sparrow HG, Swan JT, Moore LW, Gaber AO, Suki WN. Disparate outcomes observed within Kidney Disease: Improving Global Outcomes (KDIGO) acute kidney injury stage 1. Kidney Int Apr. 2019;95(4):905\u201313. https:\/\/doi.org\/10.1016\/j.kint.2018.11.030.","journal-title":"Kidney Int Apr"},{"issue":"4","key":"4884_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41581-019-0247-z","volume":"16","author":"MT James","year":"2020","unstructured":"James MT, Bhatt M, Pannu N, Tonelli M. Long-term outcomes of acute kidney injury and strategies for improved care. Nat Rev Nephrol Apr. 2020;16(4):193\u2013205. https:\/\/doi.org\/10.1038\/s41581-019-0247-z.","journal-title":"Nat Rev Nephrol Apr"},{"issue":"8","key":"4884_CR3","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.2215\/cjn.11290821","volume":"17","author":"MA Perazella","year":"2022","unstructured":"Perazella MA, Rosner MH. Drug-Induced Acute Kidney Injury. Clin J Am Soc Nephrol Aug. 2022;17(8):1220\u201333. https:\/\/doi.org\/10.2215\/cjn.11290821.","journal-title":"Clin J Am Soc Nephrol Aug"},{"issue":"3","key":"4884_CR4","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.kint.2019.10.015","volume":"97","author":"SL Goldstein","year":"2020","unstructured":"Goldstein SL, Dahale D, Kirkendall ES, et al. A prospective multi-center quality improvement initiative (NINJA) indicates a reduction in nephrotoxic acute kidney injury in hospitalized children. Kidney Int Mar. 2020;97(3):580\u20138. https:\/\/doi.org\/10.1016\/j.kint.2019.10.015.","journal-title":"Kidney Int Mar"},{"key":"4884_CR5","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jpeds.2019.08.046","volume":"215","author":"C Stoops","year":"2019","unstructured":"Stoops C, Stone S, Evans E, et al. Baby NINJA (Nephrotoxic Injury Negated by Just-in-Time Action): Reduction of Nephrotoxic Medication-Associated Acute Kidney Injury in the Neonatal Intensive Care Unit. J Pediatr Dec. 2019;215:223\u2013e2286. https:\/\/doi.org\/10.1016\/j.jpeds.2019.08.046.","journal-title":"J Pediatr Dec"},{"issue":"2","key":"4884_CR6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2215\/cjn.0000000000000044","volume":"1","author":"BR Griffin","year":"2023","unstructured":"Griffin BR, Wendt L, Vaughan-Sarrazin M, et al. Nephrotoxin Exposure and Acute Kidney Injury in Adults. Clin J Am Soc Nephrol. Feb 2023;1(2):163\u201372. https:\/\/doi.org\/10.2215\/cjn.0000000000000044.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"4884_CR7","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1177\/10600280221117993","volume":"57","author":"VL Williams","year":"2023","unstructured":"Williams VL, Smithburger PL, Imhoff AN, et al. Interventions, Barriers, and Proposed Solutions Associated With the Implementation of a Protocol That Uses Clinical Decision Support and a Stress Biomarker Test to Identify ICU Patients at High-Risk for Drug Associated Acute Kidney Injury. Ann Pharmacother Apr. 2023;57(4):408\u201315. https:\/\/doi.org\/10.1177\/10600280221117993.","journal-title":"Ann Pharmacother Apr"},{"issue":"16","key":"4884_CR8","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1161\/hc4101.096153","volume":"16","author":"AC Schoolwerth","year":"2001","unstructured":"Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation Oct. 2001;16(16):1985\u201391. https:\/\/doi.org\/10.1161\/hc4101.096153.","journal-title":"Circulation Oct"},{"issue":"12","key":"4884_CR9","doi-asserted-by":"publisher","first-page":"100918","DOI":"10.1016\/j.xkme.2024.100918","volume":"6","author":"BR Griffin","year":"2024","unstructured":"Griffin BR, Mudireddy A, Horne BD, et al. Predicting Nephrotoxic Acute Kidney Injury in Hospitalized Adults: A Machine Learning Algorithm. Kidney Med Dec. 2024;6(12):100918. https:\/\/doi.org\/10.1016\/j.xkme.2024.100918.","journal-title":"Kidney Med Dec"},{"issue":"4","key":"4884_CR10","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2215\/cjn.14021118","volume":"5","author":"C Tomson","year":"2019","unstructured":"Tomson C, Tomlinson LA. Stopping RAS Inhibitors to Minimize AKI: More Harm than Good? Clin J Am Soc Nephrol. Apr 2019;5(4):617\u20139. https:\/\/doi.org\/10.2215\/cjn.14021118.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"4884_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1159\/000505896","volume":"51","author":"SG Coca","year":"2020","unstructured":"Coca SG. Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers after Acute Kidney Injury: Friend, Foe, or Acquaintance? Am J Nephrol. 2020;51(4):263\u20135. https:\/\/doi.org\/10.1159\/000505896.","journal-title":"Am J Nephrol"},{"key":"4884_CR12","doi-asserted-by":"publisher","unstructured":"Brar S, Ye F, James MT, Hemmelgarn B, Klarenbach S, Pannu N. Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with outcomes after acute kidney injury. JAMA Intern Med. Dec 1. 2018;178(12):1681\u20131690. https:\/\/doi.org\/10.1001\/jamainternmed.2018.4749","DOI":"10.1001\/jamainternmed.2018.4749"},{"issue":"22","key":"4884_CR13","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1093\/ajhp\/zxz203","volume":"30","author":"E Goswami","year":"2019","unstructured":"Goswami E, Ogden RK, Bennett WE, et al. Evidence-based development of a nephrotoxic medication list to screen for acute kidney injury risk in hospitalized children. Am J Health Syst Pharm Oct. 2019;30(22):1869\u201374. https:\/\/doi.org\/10.1093\/ajhp\/zxz203.","journal-title":"Am J Health Syst Pharm Oct"},{"issue":"5","key":"4884_CR14","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.ajkd.2013.02.349","volume":"61","author":"PM Palevsky","year":"2013","unstructured":"Palevsky PM, Liu KD, Brophy PD, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis May. 2013;61(5):649\u201372. https:\/\/doi.org\/10.1053\/j.ajkd.2013.02.349.","journal-title":"Am J Kidney Dis May"},{"issue":"11","key":"4884_CR15","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care Nov. 2005;43(11):1130\u20139. https:\/\/doi.org\/10.1097\/01.mlr.0000182534.19832.83.","journal-title":"Med Care Nov"},{"issue":"1","key":"4884_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1053\/j.ajkd.2018.07.015","volume":"73","author":"R Malhotra","year":"2019","unstructured":"Malhotra R, Craven T, Ambrosius WT, et al. Effects of Intensive Blood Pressure Lowering on Kidney Tubule Injury in CKD: A Longitudinal Subgroup Analysis in SPRINT. Am J Kidney Dis Jan. 2019;73(1):21\u201330. https:\/\/doi.org\/10.1053\/j.ajkd.2018.07.015.","journal-title":"Am J Kidney Dis Jan"},{"issue":"11","key":"4884_CR17","first-page":"687","volume":"1","author":"MG Mercado","year":"2019","unstructured":"Mercado MG, Smith DK, Guard EL. Acute Kidney Injury: Diagnosis and Management. Am Fam Physician Dec. 2019;1(11):687\u201394.","journal-title":"Am Fam Physician Dec"},{"issue":"8","key":"4884_CR18","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/nrneph.2013.80","volume":"9","author":"MA Perazella","year":"2013","unstructured":"Perazella MA, Coca SG. Three feasible strategies to minimize kidney injury in \u2018incipient AKI\u2019. Nat Rev Nephrol Aug. 2013;9(8):484\u201390. https:\/\/doi.org\/10.1038\/nrneph.2013.80.","journal-title":"Nat Rev Nephrol Aug"},{"key":"4884_CR19","doi-asserted-by":"publisher","first-page":"665250","DOI":"10.3389\/fphar.2021.665250","volume":"12","author":"JY Chen","year":"2021","unstructured":"Chen JY, Tsai IJ, Pan HC, et al. The Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers on Clinical Outcomes of Acute Kidney Disease Patients: A Systematic Review and Meta-Analysis. Front Pharmacol. 2021;12:665250. https:\/\/doi.org\/10.3389\/fphar.2021.665250.","journal-title":"Front Pharmacol"},{"issue":"1","key":"4884_CR20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12916-020-01659-x","volume":"29","author":"P Bidulka","year":"2020","unstructured":"Bidulka P, Fu EL, Leyrat C, et al. Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care. BMC Med Jul. 2020;29(1):195. https:\/\/doi.org\/10.1186\/s12916-020-01659-x.","journal-title":"BMC Med Jul"},{"key":"4884_CR21","doi-asserted-by":"publisher","unstructured":"Gayat E, Hollinger A, Cariou A, et al. Impact of angiotensin-converting enzyme inhibitors or receptor blockers on post-ICU discharge outcome in patients with acute kidney injury. Intensive Care Med. May 2018;44(5):598\u2013605. https:\/\/doi.org\/10.1007\/s00134-018-5160-6.","DOI":"10.1007\/s00134-018-5160-6"},{"issue":"1","key":"4884_CR22","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13054-019-2447-0","volume":"29","author":"M Scarton","year":"2019","unstructured":"Scarton M, Oppenheimer A, Cha\u00efbi K, Dreyfuss D, Gaudry S. Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial. Crit Care Apr. 2019;29(1):148. https:\/\/doi.org\/10.1186\/s13054-019-2447-0.","journal-title":"Crit Care Apr"},{"issue":"1","key":"4884_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-021-00284-z","volume":"15","author":"JA Kellum","year":"2021","unstructured":"Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders HJ. Acute kidney injury. Nat Rev Dis Primers Jul. 2021;15(1):52. https:\/\/doi.org\/10.1038\/s41572-021-00284-z.","journal-title":"Nat Rev Dis Primers Jul"},{"key":"4884_CR24","doi-asserted-by":"publisher","first-page":"m4786","DOI":"10.1136\/bmj.m4786","volume":"18","author":"FP Wilson","year":"2021","unstructured":"Wilson FP, Martin M, Yamamoto Y, et al. Electronic health record alerts for acute kidney injury: multicenter, randomized clinical trial. Bmj Jan. 2021;18:372:m4786. https:\/\/doi.org\/10.1136\/bmj.m4786.","journal-title":"Bmj Jan"},{"issue":"9981","key":"4884_CR25","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/s0140-6736(15)60266-5","volume":"16","author":"FP Wilson","year":"2015","unstructured":"Wilson FP, Shashaty M, Testani J, et al. Automated, electronic alerts for acute kidney injury: a single-blind, parallel-group, randomised controlled trial. Lancet May. 2015;16(9981):1966\u201374. https:\/\/doi.org\/10.1016\/s0140-6736(15)60266-5.","journal-title":"Lancet May"},{"issue":"1","key":"4884_CR26","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1038\/s41467-023-38532-3","volume":"17","author":"FP Wilson","year":"2023","unstructured":"Wilson FP, Yamamoto Y, Martin M, et al. A randomized clinical trial assessing the effect of automated medication-targeted alerts on acute kidney injury outcomes. Nat Commun May. 2023;17(1):2826. https:\/\/doi.org\/10.1038\/s41467-023-38532-3.","journal-title":"Nat Commun May"},{"issue":"1","key":"4884_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1053\/j.ajkd.2017.06.008","volume":"71","author":"S Park","year":"2018","unstructured":"Park S, Baek SH, Ahn S, et al. Impact of Electronic Acute Kidney Injury (AKI) Alerts With Automated Nephrologist Consultation on Detection and Severity of AKI: A Quality Improvement Study. Am J Kidney Dis Jan. 2018;71(1):9\u201319. https:\/\/doi.org\/10.1053\/j.ajkd.2017.06.008.","journal-title":"Am J Kidney Dis Jan"},{"issue":"2","key":"4884_CR28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/ndt\/gfw424","volume":"1","author":"P Lachance","year":"2017","unstructured":"Lachance P, Villeneuve PM, Rewa OG, et al. Association between e-alert implementation for detection of acute kidney injury and outcomes: a systematic review. Nephrol Dial Transplant Feb. 2017;1(2):265\u201372. https:\/\/doi.org\/10.1093\/ndt\/gfw424.","journal-title":"Nephrol Dial Transplant Feb"},{"issue":"22","key":"4884_CR29","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1001\/jama.286.22.2839","volume":"12","author":"GM Chertow","year":"2001","unstructured":"Chertow GM, Lee J, Kuperman GJ, et al. Guided medication dosing for inpatients with renal insufficiency. Jama Dec. 2001;12(22):2839\u201344. https:\/\/doi.org\/10.1001\/jama.286.22.2839.","journal-title":"Jama Dec"},{"issue":"3","key":"4884_CR30","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1197\/jamia.M1727","volume":"12","author":"WL Galanter","year":"2005","unstructured":"Galanter WL, Didomenico RJ, Polikaitis A. A trial of automated decision support alerts for contraindicated medications using computerized physician order entry. J Am Med Inf Assoc May-Jun. 2005;12(3):269\u201374. https:\/\/doi.org\/10.1197\/jamia.M1727.","journal-title":"J Am Med Inf Assoc May-Jun"},{"issue":"1","key":"4884_CR31","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.kint.2016.03.031","volume":"90","author":"SL Goldstein","year":"2016","unstructured":"Goldstein SL, Mottes T, Simpson K, et al. A sustained quality improvement program reduces nephrotoxic medication-associated acute kidney injury. Kidney Int Jul. 2016;90(1):212\u201321. https:\/\/doi.org\/10.1016\/j.kint.2016.03.031.","journal-title":"Kidney Int Jul"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04884-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04884-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04884-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T01:09:44Z","timestamp":1777943384000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04884-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4884"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04884-3","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"15 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We confirm that all experiments were performed in accordance with relevant guidelines and regulations. Specifically, we obtained local institutional review board approval for this retrospective cohort analysis (University of Iowa HawkIRB 202008447). An informed consent waiver was obtained given the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"281"}}